中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

Simcere Received IND Approval for Two Immuno-oncology Bi-specific Antibodies from NMPA

Dec 29, 2022, Simcere Pharmaceutical Group (2096.HK) announced that the company has received Investigational New Drug (IND) approval from China Nation...

2022-12-30
Tsinghua University and Simcere Announce the Establishment of Joint Research Center for Innovative Drug Discovery

On Dec 23 , 022 , Tsinghua University and Simcere Pharmaceutical Group （2096.HK）today announced that they have signed a strategic collaboration agreem...

2022-12-23
PHASE II/III CLINICAL TRIAL OF SIMCERE’S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT

December 18, 2022, Simcere Pharmaceutical Group (2096.HK) announced today that, XIANNUOXIN (先諾欣TM, SIM0417), an anti-SARS-CoV-2 drug candidate jointly...

2022-12-18
PHASE III CLINICAL STUDY OF SANBEXIN SUBLINGUAL TABLETS ACHIEVED EXPECTED EFFICACY ENDPOINTS

On Dec 1,2022，Simcere Pharmaceutical Group Ltd (2096.HK), announced that, a multi-center, randomized, double-blind, parallel and placebo-controlled ph...

2022-12-02
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666 Fax：025-85262330

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.